Scientific Program - Friday 23 February

Print
Please see below the CODHy Scientific Program. Please click on the appropriate day to view the relevant program. To view the program timetable / overview, please click here
 
     
Wednesday 21 February, 2018 Thursday 22 February, 2018 Friday 23 February
Friday 23 February, 2018
HALL A
09:00-10:30
09:00-09:05

09:05-09:20
09:20-09:35

09:35-09:50
09:50-10:05
10:05-10:30
SESSION 15 – HYPERTENSION II
Chairperson
Should the guidelines favor dual combination therapy in the initial treatment of hypertension?
Yes: Ehud Grossman, Israel
No: TBC 
Should we lower the target systolic BP to 120 mm Hg?
Yes: Naftali Stern, Israel
No: TBC
Discussion
HALL B
09:00-10:30
09:00-09:05
09:05-09:20
09:20-09:40
09:40-10:00
10:00-10:15
10:05-10:30
SESSION 16 – FIGHTING OBESITY
Chairperson
Obesity: A disease or a condition? Dror Dicker, Israel
Pharmacological and non-pharmacological treatment of obesity: Present and future: Luc Van Gaal, Belgium
Metabolic surgery for diabetes prevention? Francesco Rubino, UK
Thyroid function in weight gain: Qu Shen, China 
Discussion
10:30-11:00
COFFEE BREAK
HALL A
11:00-12:30
11:00-11:05
11:05-11:25
11:25-11:45
11:45-12:05
12:05-12:30
SESSION 17 – BE AWARE OF….
Chairperson
Drug safety and efficacy: Boaz Hirshberg, USA
Hypoglycaemia: Simon Heller, UK
SGLT2 and DKA: TBC
Discussion
HALL B
11:00-12:30
11:00-11:05
11:05-11:20
11:20-11:35

11:35-11:50
11:50-12:05
12:05-12:30
SESSION 18 – RESIDUAL CV RISK IN DIABETES
Chairperson
Non-HDL cholesterol: Alberto Zambon, Italy
PCSK9 inhibitors: TBC 
How low we want LDL- Cholesterol?
Big data: TBC
RCT data: Eran Leitersdorf, Israel
Discussion
HALL A
12:30-14:00
12:30-12:35
12:35-12:55
12:55-13:15
13:15-13:35
13:35-14:00
SESSION 19 – NEW PLAYERS IN T2DM
Chairperson
NAFLD/NASH: Ran Oren, Israel
Microbioma: Karsten Kristiansen, Denmark
CVOT- what’s next? Eberhard Standl, Germany
Discussion
HALL B
12:30-14:00
12:30-12:35
12:35-12:55
12:55-13:15
13:15-13:35
13:35-14:00
SESSION 20 – DIABETES AND HEART FAILURE
Chairperson
Diabetic cardiomyopathy: Angelo Avogaro, Italy
KB and heart function: Riccardo Bonadonna, Italy
HF and anti-hyperglycemic drugs: Mikhail Kosiborod, USA
Discussion